- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02732275
DS-3201b in Participants With Lymphomas
A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas
DS-3201b is an experimental drug. It is not approved for regular use. It can only be used in clinical research.
Adults with non-Hodgkin lymphoma (NHL) might be able to join this study if their disease:
- has come back after remission
- is not responding to current treatment
This study has three parts:
- Dose Escalation is to find the safe dose of DS-3201b that adults with advanced NHL can tolerate.
Dose Expansion is to:
- find out how effective DS-3201b is for rare types of NHL
- collect additional safety data
- Drug-Drug Interaction (DDI) Cohort (US Only) is to evaluate the effect of DS-3201b on the pharmacokinetics (PK) midazolam and digoxin when co-administered to patients with NHL
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Aichi
-
Nagoya-shi, Aichi, Japan, 467-8602
- Nagoya City University Hospital
-
-
Chiba
-
Kahiwa-shi, Chiba, Japan, 277-8577
- National Cancer Center Hospital East
-
-
Iwate
-
Morioka-shi, Iwate, Japan, 020-8505
- Iwate Medical University Hospital
-
-
Kagoshima
-
Kagoshima-shi, Kagoshima, Japan, 890-0064
- Imamura General Hospital
-
Kagoshima-shi, Kagoshima, Japan, 890-8520
- Kagoshima University Hospital
-
-
Kumamoto
-
Kumamoto-shi, Kumamoto, Japan, 860-8556
- Kumamoto University Hosipital
-
-
Nagasaki
-
Nagasaki-shi, Nagasaki, Japan, 852-8501
- Nagasaki University Hospital
-
-
Okinawa
-
Nakagami-gun, Okinawa, Japan, 903-0215
- University of the Ryukyus Hospital
-
-
Tokyo
-
Minato-ku, Tokyo, Japan, 108-8639
- The Institute of Medical Science, The University of Tokyo
-
-
Toyko
-
Chuo Ku, Toyko, Japan, 104-0045
- National Cancer Center Hospital
-
-
-
-
California
-
Duarte, California, United States, 91010
- City of Hope National Medical Center
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520-8064
- Yale University
-
-
Georgia
-
Atlanta, Georgia, United States, 30322-1013
- Emory University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215-5418
- Dana-Farber Cancer Institute
-
-
New Jersey
-
Hackensack, New Jersey, United States, 07601
- Hackensack University Medical Center
-
-
New York
-
New York, New York, United States, 10021
- Weill Cornell Medicine
-
New York, New York, United States, 10065-6007
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University Wexner Medical Center and James Cancer Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107-5001
- Thomas Jefferson University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has hematocytological or pathological diagnosis of non- Hodgkin's lymphoma (NHL)
- Has relapsed from or is refractory to standard treatment or no standard treatment is available
- Is the age of majority in their country (18 in the US and 20 in Japan) at the time of informed consent
- Has Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Has at least one evaluable lesion site (not applicable for the DDI cohort)
- Has preserved organ function based on baseline laboratory data at screening tests
- If of reproductive potential, agrees to avoid harvesting ova or sperm, and to use a protocol-defined form of contraception or avoid intercourse, during and upon completion of the study, and for at least 3 months after the last dose of study drug
Tumor biopsy collections:
- willing to provide archived or fresh tumor tissue samples that are sufficient for comprehensive genomic and/or proteomic analyses at baseline
[US only] willing to provide fresh on-treatment tumor biopsy if deemed acceptable risk by the investigator
[Japan only] fresh on-treatment tumor biopsy should be performed if deemed acceptable risk by the investigator
- willing to provide optional fresh end-of-treatment biopsy
For ATL subjects:
- Has a positive test result for human T-lymphotropic virus type I antibody
- Has ATL subtype classified as acute, lymphomatous, or chronic with poor prognostic factor
- Has diagnosis of relapse (including relapse after partial remission [PR]) or treatment-resistant ATL at the time of informed consent after prior treatment with at least 1 anti-cancer medication regimen
Exclusion Criteria:
- Has been diagnosed with protocol-defined cutaneous T-cell lymphoma or T-cell leukemia. For DDI cohort, CTCL is not exclusionary.
- Has a history or presence of central nervous system (CNS) involvement
- Has a medical history, complication or other malignancy considered inappropriate for participation in the study, or a serious physical or psychiatric disease, the risk of which may be increased by participation in the study
- Has received drugs or other treatments not allowed by the protocol
- History of treatment with other enhancer of zeste (EZH) inhibitors
- Has had allogeneic hematopoietic stem cell transplantation (HTCP) within 90 days before scheduled dosing on Cycle 1 Day 1
- Is pregnant or breastfeeding
- Is otherwise deemed ineligible to participate by the investigator or sub-investigator
DDI Cohort Only:
- Has received following medications within 14 days prior to study drug administration
- Any CYP3A inhibitors/inducers including weak CYP3A inhibitors/inducers, and P-gp inhibitors, midazolam as well as digoxin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DS-3201b
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose Escalation Period: Number of participants with dose-limiting toxicities (DLTs)
Time Frame: within 28 days after the initial dose of the study drug
|
Number of DLT-evaluable participants with protocol-defined DLTs
|
within 28 days after the initial dose of the study drug
|
Dose Escalation Period: Maximum concentration (Cmax) of DS-3201
Time Frame: within the first 28-day cycle
|
Categories: Cycle 1 Day 1, Cycle 1 Day 15
|
within the first 28-day cycle
|
Dose Escalation Period: Time of maximum concentration (Tmax) of DS-3201
Time Frame: within the first 28-day cycle
|
Categories: Cycle 1 Day 1, Cycle 1 Day 15
|
within the first 28-day cycle
|
Dose Escalation Period: Area under the plasma concentration time curve up to the last quantifiable time (AUClast) for DS-3201
Time Frame: Day 1 of the first 28-day cycle
|
Day 1 of the first 28-day cycle
|
|
Dose Escalation Period: Area under the plasma concentration time curve during the dosing interval (AUCtau) for DS-3201
Time Frame: Day 1 of the first 28-day cycle
|
Day 1 of the first 28-day cycle
|
|
Dose Escalation Period: Trough (minimum) plasma concentration (Ctrough)
Time Frame: Day 15 of the first 28-day cycle
|
Day 15 of the first 28-day cycle
|
|
Dose Escalation Period: Average plasma concentration (Cavg)
Time Frame: Day 15 of the first 28-day cycle
|
Day 15 of the first 28-day cycle
|
|
DDI cohort only: Maximum concentration (Cmax) of DS-3201, midazolam, digoxin
Time Frame: within the first 28-day cycle
|
Categories: Day -4, Cycle 1 Day 1, Cycle 1 Day 15
|
within the first 28-day cycle
|
DDI cohort only: Time of maximum concentration (Tmax) of DS-3201, midazolam, digoxin
Time Frame: within the first 28-day cycle
|
Categories: Day -4, Day 0 (for alternate schedule), Cycle 1 Day 1, Cycle 1 Day 15
|
within the first 28-day cycle
|
DDI cohort only: Area under the plasma concentration time curve up to the last quantifiable time (AUClast) for DS-3201,midazolam,digoxin
Time Frame: within the first 28-day cycle
|
Categories: Day -4, Day 0 (for alternate schedule), Cycle 1 Day 1, Cycle 1 Day 15
|
within the first 28-day cycle
|
DDI cohort only: Area under the plasma concentration time curve during the dosing interval (AUCtau) for DS-3201, midazolam, digoxin
Time Frame: within the first 28-day cycle
|
Cycle 1 Day 1, Cycle 1 Day 15
|
within the first 28-day cycle
|
Number of participants with treatment-emergent adverse events (TEAEs)
Time Frame: through the end of the study (within approximately 5 years)
|
TEAEs are systematically collected from lab values, physical exams, and other investigations
|
through the end of the study (within approximately 5 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best overall response, based on international consensus criteria
Time Frame: from the start of study treatment to the end of follow-up visit (within 5 years)
|
Best overall response is defined as the percentage of participants who achieved each category as the best response, considering all overall responses assessed at all time points after the start of study treatment. Categories: CR, CRu, PR, SD, RD/PD, UA Categories: Malignant lymphoma, ATL, CTCL |
from the start of study treatment to the end of follow-up visit (within 5 years)
|
Objective response rate (ORR)
Time Frame: within 5 years
|
ORR is defined as the percentage of participants who were assessed for best overall response, who achieved CR, UCR, or PR
|
within 5 years
|
Disease control rate (DCR)
Time Frame: within 5 years
|
DCR is defined as the percentage of participants who were assessed for best overall response, who achieved a best response of CR, UCR, PR, or SD
|
within 5 years
|
Duration of response (DOR)
Time Frame: within 5 years
|
DOR is defined as the time from the date at which criteria are first met for CR or PR (including CRu for ATL) until the first date that progressive disease is objectively documented.
|
within 5 years
|
Progression-free survival (PFS)
Time Frame: witihn 5 years
|
PFS is defined as the time from the date of the first dose to the earlier of the dates of the first objective documentation of disease progression or death due to any cause.
|
witihn 5 years
|
Number of participants with malignant lymphoma who achieved each level of therapeutic response per international consensus standards
Time Frame: through the end of the study (within approximately 5 years)
|
Categories: Complete remission (CR), Partial remission (PR), Stable disease (SD), Relapsed disease or progressive disease (RD/PD)
|
through the end of the study (within approximately 5 years)
|
Number of participants with ATL who achieved each level of therapeutic response per international consensus standards
Time Frame: through the end of the study (within approximately 5 years)
|
Categories: CR, Uncertified complete remission (CRu), PR, SD, RD/PD, Unassessable (UA)
|
through the end of the study (within approximately 5 years)
|
Number of participants with CTCL who achieved response per 2011 CTCL criteria
Time Frame: through the end of the study (within approximately 5 years)
|
Categories: CR,PR,SD,PD,Relapse
|
through the end of the study (within approximately 5 years)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DS3201-A-J101
- 163173 (Registry Identifier: JAPIC CTI)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Malignant
-
Stephen CoubanGenzyme, a Sanofi CompanyCompletedMalignant Lymphoma, Stem Cell TypeCanada
-
State Budgetary Healthcare Institution, National...UnknownRelapsed/Refractory Malignant LymphomasRussian Federation
-
Cao Pharmaceuticals Inc.The University of Texas Health Science Center at San AntonioUnknownSolid Tumor | Malignant Lymphoma of Extranodal and/or Solid Organ SiteUnited States
-
InnoPharmax Inc.CompletedAdvanced Solid Malignancies | Malignant LymphomasTaiwan
-
Shanghai Junshi Bioscience Co., Ltd.Active, not recruitingRecurrent/Refractory Malignant LymphomaChina
-
Philips HealthcarePhilips Electronics Nederland B.V. acting through Philips CTO organizationCompletedMalignant Lymphoma of Lymph Nodes of Inguinal Region | Malignant Lymphoma of Lymph Nodes of Axillary | Malignant Lymphoma of Lymph Nodes of the Cervix | Carcinoma of Parotid Gland | Colon Rectal Cancer Tubulovillous Adenocarcinoma | Tumor of Soft Tissue of Head, Face and NeckNetherlands
-
National Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid NeoplasmUnited States
-
4SC AGCompletedMalignant Lymphomas | Advanced and Incurable Solid TumorsGermany
-
National Cancer Institute (NCI)WithdrawnLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin LymphomaUnited States
-
University Hospital, LimogesCompletedHodgkin's Disease | Malignant Lymphomas High Grade | ChemoresistanceFrance
Clinical Trials on DS-3201b
-
Daiichi Sankyo, Inc.TerminatedLeukemia, Myeloid, Acute | Leukemia, Lymphocytic, AcuteUnited States
-
Daiichi Sankyo, Inc.CompletedHepatic ImpairmentUnited States
-
Daiichi Sankyo Co., Ltd.Active, not recruitingAdult T-cell Leukemia/LymphomaJapan
-
The Lymphoma Academic Research OrganisationDaiichi SankyoActive, not recruitingStudy of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell LymphomaLymphoma, B-CellFrance, Belgium
-
Daiichi Sankyo, Inc.Active, not recruitingRelapsed/Refractory Peripheral T-Cell Lymphoma | Adult T Cell Leukemia/LymphomaUnited States, Spain, Japan, United Kingdom, Korea, Republic of, France, Italy, Australia, Canada, Germany, Netherlands, Taiwan
-
Daiichi Sankyo, Inc.Not yet recruitingAdvanced Solid Tumor
-
Memorial Sloan Kettering Cancer CenterCompletedSmall Cell Lung CancerUnited States
-
Ludwig Institute for Cancer ResearchDaiichi Sankyo Co., Ltd.; Austin HealthCompletedMalignant Solid Tumor | Metastatic EphA2 Positive CancerAustralia
-
Daiichi Sankyo Co., Ltd.RecruitingSolid Tumor | Metastatic Solid Tumor | Advanced CancerJapan, United States, Canada
-
Daiichi Sankyo Co., Ltd.CompletedAdvanced Solid Malignant TumorsJapan